VWR Corporation (NASDAQ:VWR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $37.00 target price on the medical research company’s stock. Zacks Investment Research‘s price target points to a potential upside of 11.78% from the stock’s previous close.

According to Zacks, “VWR’s second-quarter earnings report was quite impressive, with both the top and the bottom line beating the Zacks Consensus Estimate. Geographically, the company recorded growth in Americas during the reported quarter driven by strong sales of equipment and instrumentation. Management is also looking forward to the long-term synergy benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. While we await the merger to close in the fourth quarter of 2017 we note that the stock price has already reached close to Avantor’s offer price and hence the short-term upside potential of VWR is limited now. On the flip side, a drop in EMEA-APAC sales was disappointing. Moreover, foreign currency was a major dampener. VWR’s poor margin scenario also raises concern.”

Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of VWR Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. William Blair lowered shares of VWR Corporation from an “outperform” rating to a “market perform” rating in a research note on Monday, May 15th. Finally, ValuEngine upgraded shares of VWR Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $31.67.

Shares of VWR Corporation (NASDAQ VWR) traded down 0.045% on Tuesday, hitting $33.085. 124,969 shares of the stock were exchanged. The company’s 50 day moving average is $33.01 and its 200-day moving average is $31.24. The stock has a market cap of $4.36 billion, a PE ratio of 30.634 and a beta of 1.19. VWR Corporation has a 52-week low of $24.42 and a 52-week high of $37.25.

VWR Corporation (NASDAQ:VWR) last released its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the firm earned $0.42 earnings per share. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. Analysts predict that VWR Corporation will post $1.87 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “VWR Corporation (VWR) Upgraded at Zacks Investment Research” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/12/vwr-corporation-vwr-upgraded-at-zacks-investment-research.html.

Several hedge funds have recently bought and sold shares of the company. Madison Dearborn Partners LLC acquired a new stake in shares of VWR Corporation in the second quarter valued at approximately $1,553,375,000. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of VWR Corporation by 1.3% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 7,405,287 shares of the medical research company’s stock valued at $214,012,000 after acquiring an additional 93,375 shares during the period. Vanguard Group Inc. boosted its holdings in shares of VWR Corporation by 5.3% in the first quarter. Vanguard Group Inc. now owns 6,827,046 shares of the medical research company’s stock valued at $192,523,000 after acquiring an additional 345,117 shares during the period. Harris Associates L P boosted its holdings in shares of VWR Corporation by 43.3% in the first quarter. Harris Associates L P now owns 5,250,960 shares of the medical research company’s stock valued at $148,077,000 after acquiring an additional 1,587,214 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of VWR Corporation by 167.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 5,048,234 shares of the medical research company’s stock valued at $142,916,000 after acquiring an additional 3,163,988 shares during the period.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Get a free copy of the Zacks research report on VWR Corporation (VWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.